司库奇尤单抗对活动性银屑病关节炎患者报告结局的影响:一项随机3期试验
FUTURE 5 3期随机试验纳入活动性银屑病关节炎患者,随机接受司库奇尤单抗300 mg、150 mg、150 mg无负荷剂量或安慰剂。第16周时,除SF-36精神成分摘要外,各司库奇尤单抗组在患者报告结局上较安慰剂均有显著改善,且与既往TNF抑制剂使用无关。
要点
- 第16周时各司库奇尤单抗剂量组在多数患者报告结局上较安慰剂显著改善,仅SF-36精神成分摘要例外。
- 患者总体疾病活动评估、疼痛VAS、HAQ-DI和FACIT-F的改善在所有司库奇尤单抗组均显著优于安慰剂(均p<0·0001)。
- 达到MCID改善的患者比例在多数患者报告结局上司库奇尤单抗组高于安慰剂组,与既往TNF抑制剂使用无关。
核心结论
- 司库奇尤单抗在所有剂量下较安慰剂对活动性银屑病关节炎患者的患者报告结局产生早期、有统计学显著性和临床意义且持续的改善。
- 这些改善在事后分析中与既往是否使用TNF抑制剂无关。
- 作者认为司库奇尤单抗为银屑病关节炎患者提供全面改善,无论既往治疗如何。
研究设计与样本
- FUTURE 5(NCT02404350)是一项3期、多中心、平行组随机试验。
- 纳入18岁及以上、符合银屑病关节炎分类标准且中重度症状持续至少6个月的患者。
- 患者随机接受司库奇尤单抗300 mg、150 mg、150 mg无负荷剂量或安慰剂,基线至第4周每周给药,此后每4周给药。
- 预设患者报告结局先在总体人群中评估,随后按TNF抑制剂状态(TNF初治和TNF应答不足人群)分层进行事后分析。
主要发现
- 第16周时,所有司库奇尤单抗组在除SF-36精神成分摘要外的所有患者报告结局上较安慰剂的最小二乘均值变化均有显著性,与TNF抑制剂使用无关。
- 患者总体疾病活动评估较安慰剂差异:300 mg组-12·2(95%CI -16·3至-8·1),150 mg组-8·22(-12·4至-4·1),150 mg无负荷剂量组-8·3(-12·5至-4·2),均p<0·0001。
- 疼痛VAS较安慰剂差异:300 mg组-14·3(-18·3至-10·2),150 mg组-11·5(-15·6至-7·5),150 mg无负荷剂量组-11·3(-15·3至-7·2),均p<0·0001。
- HAQ-DI较安慰剂差异:300 mg组-0·33(-0·42至-0·24),150 mg组-0·23(-0·32至-0·14),150 mg无负荷剂量组-0·24(-0·33至-0·15),均p<0·0001。
- FACIT-F较安慰剂差异:300 mg组4·8(3·2至6·4),150 mg组4·2(2·6至5·8),150 mg无负荷剂量组3·5(1·9至5·1),均p<0·0001。
关键数值与推荐
- 第16周达到MCID或以上改善的患者比例在多数患者报告结局上司库奇尤单抗组高于安慰剂组,SF-36精神成分摘要除外,与TNF抑制剂使用无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase 3 FUTURE 5 trial (NCT02404350) showed the clinical and radiographical efficacy of secukinumab in patients with psoriatic arthritis. This analysis aimed to assess the effect of secukinumab on patient-reported outcomes (PROs). METHODS: FUTURE 5 was a phase 3, multicentre, parallel-group randomised trial in which patients who were 18 years old or older, met the classification criteria for psoriatic arthritis at screening, and had symptoms of moderate-to-severe psoriatic arthritis for at least 6 months were randomly assigned to receive secukinumab 300 mg, 150 mg, 150 mg no loading dose (NL), or placebo weekly from baseline to week 4 and every 4 weeks thereafter. The prespecified PROs of the FUTURE 5 trial were assessed first in the overall population. We report mean changes from baseline and the proportion of patients reporting improvements equal to or more than the minimum clinically important differences (MCIDs) and scores equal to or more than the normative values for patient global assessments (PtGA) of disease activity; psoriasis and arthritis visual analogue scale (VAS) scores; pain VAS; Health Assessment Questionnaire Disability Index (HAQ-DI); 36-item Short Form Health Survey (SF-36); Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F); and quality of life questionnaires. Patients were then stratified and assessed according to their tumour necrosis factor (TNF) inhibitor status (TNF-naive and TNF-inadequate responder [TNF-IR] populations) as a post-hoc analysis. FINDINGS: Patients in all secukinumab groups reported significant least-squares mean changes from placebo at week 16 in all PROs except SF-36 mental component summary (MCS), irrespective of TNF inhibitor use. These included PtGA (300 mg difference vs placebo -12·2 [95% CI -16·3 to -8·1], 150 mg -8·22 [-12·4 to -4·1], 150 mg NL -8·3 [-12·5 to -4·2]; all p<0·0001), pain VAS (300 mg -14·3 [-18·3 to -10·2], 150 mg -11·5 [-15·6 to -7·5], 150 mg NL -11·3 [-15·3 to -7·2]; all p<0·0001), HAQ-DI (300 mg -0·33 [-0·42 to -0·24], 150 mg -0·23 [-0·32 to -0·14], 150 mg NL -0·24 [-0·33 to -0·15]; all p<0·0001), and FACIT-F (300 mg 4·8 [3·2 to 6·4], 150 mg 4·2 [2·6 to 5·8], 150 mg NL 3·5 [1·9 to 5·1]; all p<0·0001). Similarly, the proportion of patients with improvements equal to or better than MCID at week 16 was higher in the secukinumab group compared with the placebo group for most PROs except SF-36 (MCS), regardless of TNF inhibitor use. INTERPRETATION: Secukinumab resulted in early, statistically significant, clinically meaningful, sustained improvements in PROs across all doses compared with placebo in patients with active psoriatic arthritis. These improvements were seen irrespective of previous TNF inhibitor use, in a post-hoc analysis. These results indicate that secukinumab provides comprehensive improvement for patients with psoriatic arthritis, regardless of previous therapy. FUNDING: Novartis.
引用
- Strand V, Kaeley GS, Bergman MJ, et al. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. Lancet Rheumatol. 2022. PMID: 38288937. doi:10.1016/S2665-9913(21)00354-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。